Liver dysfunction is associated with poor prognosis in patients after immune checkpoint inhibitor therapy

被引：13

作者：

Yokohama, Keisuke ^{[1
]}

Asai, Akira ^{[1
]}

Matsui, Masahiro ^{[1
]}

Okamoto, Norio ^{[1
]}

Yasuoka, Hidetaka ^{[1
]}

Nishikawa, Tomohiro ^{[2
]}

Ohama, Hideko ^{[1
]}

Tsuchimoto, Yusuke ^{[1
]}

Inoue, Yoshihiro ^{[3
]}

Fukunishi, Shinya ^{[1
]}

Uchiyama, Kazuhisa ^{[3
]}

Higuchi, Kazuhide ^{[1
]}

机构：

[1] Osaka Med Coll, Dept Internal Med 2, 2-7 Daigakumachi, Takatsuki, Osaka 5698686, Japan

[2] Hokusetsu Gen Hosp, Internal Med, Takatsuki, Osaka, Japan

[3] Osaka Med Coll, Dept Gen & Gastroenterol Surg, Takatsuki, Osaka, Japan

来源：

SCIENTIFIC REPORTS | 2020年 / 10卷 / 01期

关键词：

ADVERSE EVENTS; ADVANCED MELANOMA; SINGLE-ARM; OPEN-LABEL; NIVOLUMAB; PEMBROLIZUMAB; MULTICENTER; PD-1; CHEMOTHERAPY; IPILIMUMAB;

D O I：

10.1038/s41598-020-71561-2

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Immune-related adverse events (irAEs) are induced by immune checkpoint inhibitors (ICI s). Liver is one of the main target organs which irAEs occur and we investigated the influence of liver dysfunction on prognosis of patients after ICIs. From July 2014 to December 2018, 188 patients with diverse cancers who received ICI s (nivolumab or pembrolizumab) were enrolled. Twenty-nine patients experienced liver dysfunction of any grades after ICIs. Progression-free survival (PFS) was significantly shorter in the liver dysfunction-positive group than in the liver dysfunction-negative group, and a similar result was obtained for Overall survival (OS). Multiple logistic regression analysis revealed liver metastasis and alanine aminotransferase before ICI s were associated with a higher incidence of liver dysfunction after ICIs. Regardless of liver metastasis, PFS and OS were significantly shorter in the liver dysfunction-positive group. In conclusion, this study suggests liver dysfunction is associated with poor prognosis in patients after ICI s with diverse cancers.

引用

页数：9

共 50 条

[31] Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer [J].

Touat, Mehdi ;

Maisonobe, Thierry ;

Knauss, Samuel ;

Salem, Omar Ben Hadj ;

Hervier, Baptiste ;

Aure, Karine ;

Szwebel, Tali-Anne ;

Kramkimel, Nora ;

Lethrosne, Claire ;

Bruch, Jean-Frederic ;

Laly, Pauline ;

Cadranel, Jacques ;

Weiss, Nicolas ;

Behin, Anthony ;

Allenbach, Yves ;

Benveniste, Olivier ;

Lenglet, Timothee ;

Psimaras, Dimitri ;

Stenzel, Werner ;

Leonard-Louis, Sarah .

NEUROLOGY, 2018, 91 (10) :E985-E994

[32] Effects of immune checkpoint inhibitor therapy resumption in patients with malignant tumors after moderate-to-severe immune-related adverse events [J].

Kawahira, Machiko ;

Kanmura, Shuji ;

Mizuno, Keiko ;

Machida, Kentaro ;

Ohtsuka, Takao ;

Sato, Masami ;

Enokida, Hideki ;

Yamashita, Masaru ;

Kanekura, Takuro ;

Arima, Shiho ;

Nakamura, Norifumi ;

Sugiura, Tsuyoshi ;

Yoshimoto, Koji ;

Kobayashi, Hiroaki ;

Ishitsuka, Kenji ;

Suzuki, Shinsuke ;

Ueno, Shinichi ;

Ido, Akio .

PLOS ONE, 2022, 17 (04)

[33] High Serum PD-L1 Levels Are Associated with Poor Survival in Urothelial Cancer Patients Treated with Chemotherapy and Immune Checkpoint Inhibitor Therapy [J].

Krafft, Ulrich ;

Olah, Csilla ;

Reis, Henning ;

Kesch, Claudia ;

Darr, Christopher ;

Grunwald, Viktor ;

Tschirdewahn, Stephan ;

Hadaschik, Boris ;

Horvath, Orsolya ;

Kenessey, Istvan ;

Nyirady, Peter ;

Varadi, Melinda ;

Modos, Orsolya ;

Csizmarik, Anita ;

Szarvas, Tibor .

CANCERS, 2021, 13 (11)

[34] Immune checkpoint inhibitor-related thyroid dysfunction [J].

Illouz, Frederic ;

Briet, Claire ;

Rodien, Patrice .

ANNALES D ENDOCRINOLOGIE, 2023, 84 (03) :346-350

[35] Rate of response to immune checkpoint inhibitor therapy in patients with conjunctival melanoma [J].

Esmaeli, Bita ;

Ogden, Tyler ;

Nichols, Matthew ;

Lu, Tracy ;

Debnam, J. Matthew ;

Dimitriou, Florentia ;

Mcquade, Jennifer ;

Oliva, Isabella C. Glitza .

MELANOMA RESEARCH, 2025, 35 (02) :130-144

[36] Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy [J].

Kumar, Vivek ;

Chaudhary, Neha ;

Garg, Mohit ;

Floudas, Charalampos S. ;

Soni, Parita ;

Chandra, Abhinav B. .

FRONTIERS IN PHARMACOLOGY, 2017, 8

[37] Immune Checkpoint Inhibitor Therapy Key principles when educating patients [J].

Wood, Laura S. ;

Moldawer, Nancy P. ;

Lewis, Colleen .

CLINICAL JOURNAL OF ONCOLOGY NURSING, 2019, 23 (03) :271-280

[38] Repeat Treatment of Patients With Advanced Urothelial Carcinoma With Immune Checkpoint Inhibitors Following Prior Progression on a Checkpoint Inhibitor Regimen: A Case Series [J].

Jindal, Tanya ;

Chou, Jonathan ;

Friedlander, Terence ;

Barata, Pedro C. ;

Koshkin, Vadim S. .

CLINICAL GENITOURINARY CANCER, 2022, 20 (02) :189-194

[39] Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings [J].

Wang, Gary X. ;

Kurra, Vikram ;

Gainor, Justin F. ;

Sullivan, Ryan J. ;

Flaherty, Keith T. ;

Lee, Susanna I. ;

Fintelmann, Florian J. .

RADIOGRAPHICS, 2017, 37 (07) :2132-2144

[40] The landscape of immune checkpoint inhibitor therapy in advanced lung cancer [J].

Wang, Chengdi ;

Li, Jingwei ;

Zhang, Qiran ;

Wu, Jiayang ;

Xiao, Yuxuan ;

Song, Lujia ;

Gong, Hanlin ;

Li, Yalun .

BMC CANCER, 2021, 21 (01)

← 1 2 3 4 5 →